SPEXIS
Polyphor is a Swiss Pharma company focusing on the discovery and development of macrocycle drugs addressing high unmet medical needs. Polyphor was founded in 1996 and is a clinical stage, privately held Swiss specialty pharma company, based in Allschwil near Basel. It focuses on the development of macrocycle drugs that address antibiotic resistance and severe respiratory diseases.
SPEXIS
Industry:
Biotechnology Medical Pharmaceutical
Founded:
1996-01-01
Address:
Allschwil, Basel-Landschaft, Switzerland
Country:
Switzerland
Website Url:
http://www.spexisbio.com
Total Employee:
11+
Status:
Active
Contact:
41615671601
Total Funding:
94.97 M USD
Technology used in webpage:
Domain Not Resolving Euro SPF Microsoft Exchange Online Office 365 Mail Microsoft DNS
Similar Organizations
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
PaxVax
PaxVax is a start-up developing candidate oral vaccines for key infectious diseases.
PhaseBio Pharmaceuticals
PhaseBio is a clinical-stage biopharmaceutical company that develops drugs for cardiovascular diseases, endocrine, and metabolic disorders.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Salix Pharmaceuticals
Salix Pharmaceuticals is a specialty pharmaceutical company focused on the prevention and treatment of gastrointestinal disorders.
Versameb
Versameb is focusing on the discovery and development of innovative, next-generation RNA-based drugs.
Current Advisors List
Board_member
Board_member
Current Employees Featured
Daniel Obrecht CSO @ Spexis
CSO
1997-02-01
Jean-Pierre Obrecht CEO @ Spexis
CEO
Marc Thommen Head of Technology Platforms @ Spexis
Head of Technology Platforms
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-09-01 | EnBiotix | EnBiotix acquired by Spexis | N/A |
Investors List
SPRIM Global Investments
SPRIM Global Investments investment in Post-IPO Debt - Spexis
SPRIM Global Investments
SPRIM Global Investments investment in Post-IPO Equity - Spexis
SPRIM Global Investments
SPRIM Global Investments investment in Debt Financing - Spexis
CARB-X
CARB-X investment in Grant - Spexis
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation investment in Grant - Spexis
CARB-X
CARB-X investment in Grant - Spexis
CARB-X
CARB-X investment in Grant - Spexis
Repair Impact Fund
Repair Impact Fund investment in Post-IPO Equity - Spexis
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - Spexis
New Medical Technologies
New Medical Technologies investment in Venture Round - Spexis
Official Site Inspections
http://www.spexisbio.com Semrush global rank: 4.92 M Semrush visits lastest month: 1.74 K
- Host name: s062.cyon.net
- IP address: 149.126.4.71
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "Spexis"
About Spexis – Spexis
Who we are. Spexis AG (SIX:SPEX) is a clinical-stage, publicly-listed biopharmaceutical company focused on discovering and developing first-in-class macrocyclic molecules for rare diseases and cancer.The most advanced of …See details»
Spexis AG – Swiss Biotech
Spexis AG (SIX:SPEX) is a clinical-stage biotech company focused on first-in-class macrocyclic drugs for cancer & rare diseases. >25 years and $400M of R & D has resulted in three clinical …See details»
Annual Report 2021 - spexisbio.com
The Cystic Fibrosis Foundation the leading patient advocacy and philanthropic organization servicing the needs of CF patients and their caretakers worldwide - also participated in our …See details»
Spexis - VentureRadar
Similar Companies: Dansk Biotek Unknown n/a DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, …See details»
Spexis Company Profile 2024: Stock Performance
The company's lead product, murepavadin, is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by World Health Organization. It has one operating segment focusing on the research …See details»
Spexis - Overview, News & Similar companies | ZoomInfo.com
Spexis contact info: Phone number: +41 615671600 Website: www.spexisbio.com What does Spexis do? Spexis is a company that specializes in the manufacturing of pharmaceuticals with …See details»
Spexis - Company Profile - Tracxn
Nov 15, 2024 Developer of antibiotic therapeutics for the treatment of cancer and rare diseases. The product pipeline of the company includes ColiFin for cystic fibrosis, EBX-002, a …See details»
Spexis Provides Business Update and Announces Financial
Mar 24, 2022 IR@spexisbio.com. For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 feldhaus@feldhaus-partner.ch. About Spexis Spexis is a clinical-stage …See details»
Spexis provides business update and announces financial
May 30, 2023 Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on rare diseases and oncology. For further information please …See details»
General contact – Spexis
For general information, please contact us. Spexis AG Hegenheimermattweg 125 CH-4123 Allschwil Switzerland T: +41 61 567 16 00 info@spexisbio.comSee details»
Spexis Provides Business Update and Announces Financial Results …
Mar 24, 2022 Successful launch of Spexis AG as a reverse merger of Polyphor AG with EnBiotix Inc. Successful closing of a USD 12.8 million pre-merger financingSee details»
Spexis announces sale of preclinical antibiotics program to Basilea
Jan 15, 2024 In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, of which nine classes are …See details»
Spexis provides business update and announces financial results …
May 30, 2023 Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient …See details»
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., …
Sep 28, 2023 ALLSCHWIL, Switzerland, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and …See details»
Careers – Spexis
Working at Spexis We motivate and retain passionate and persevering professionals with an entrepreneurial spiritSee details»
Spexis announces sale of preclinical antibiotics program to Basilea
Jan 15, 2024 In 2017, the World Health Organization published a list of 12 classes of priority bacterial pathogens that pose the greatest threat to human health, ... www.spexisbio.com.See details»
Spexis provides business update and announces financial
Sep 29, 2023 IR@spexisbio.com. Or. Stephen Jasper Managing Director Gilmartin Group stephen@gilmartinir.com. For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 …See details»
Spexis provides business update and announces financial
Sep 6, 2022 IR@spexisbio.com: For Media: Dr. Stephan Feldhaus Feldhaus & Partner +41 79 865 92 56 feldhaus@feldhaus-partner.ch: Raimund Gabriel MC Services spexis@mc …See details»
News – Spexis
Oct 9, 2023 Original-Research: Spexis AG - von First Berlin Equity Research GmbH Einstufung von First Berlin Equity Research GmbH zu Spexis AG Unternehmen: Spexis AG ISIN: …See details»